EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer

Li-Jun Wei, Jia Fu, Hai-Xia Yang, Xia Yang, Hao-Yu Liang, Rong-Zhen Luo, Li-Li Liu iD

Journal of Translational Medicine · 2024

DOI: 10.1186/s12967-024-05482-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Medicine, 2024. Verfasst von Li-Jun Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Uterine Cervical Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemotherapy (NACT) is a viable therapeutic option for women diagnosed locally advanced cervical cancer (LACC). However, the factors influencing pathological response are still controversial. We collected pair specimens of 185 LACC patients before and after receiving NACT and conducted histological evaluation. 8 fresh tissues pre-treatment were selected from the entire cohort to conducted immune gene expression profiling. A novel pathological grading system was established by comprehensively assessing the percentages of viable tumor, inflammatory stroma, fibrotic stroma, and necrosis in the tumor bed. Then, 185 patients were categorized into either the good pathological response (GPR) group or the poor pathological response (PPR) group post-NACT, with 134 patients (72.4%, 134/185) achieving GPR. Increasing tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating lymphocytes volume (TILV) pre-treatment were correlated with GPR, with TILV emerging as an independent predictive factor for GPR. Additionally, CIBERSORT analysis revealed noteworthy differences in the expression of immune makers between cPR and non-cPR group. Furthermore, a significantly heightened density of CD8 + T cells and a reduced density of FOXP3 + T cells were observed in GPR than PPR. Importantly, patients exhibiting GPR or inflammatory type demonstrated improved overall survival and disease-free survival. Notably, stromal type was an independent prognostic factor in multivariate analysis. Our study indicates the elevated TILV in pre-treatment specimens may predict a favorable response to NACT, while identifying stromal type in post-treatment specimens as an independent prognostic factor. Moreover, we proposed this pathological grading system in NACT patients, which may offer a more comprehensive understanding of treatment response and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyUterine Cervical NeoplasmsLymphocytes, Tumor-InfiltratingTreatment OutcomePrognosisInflammationHumansFemaleAdultMiddle AgedAgedCD8-Positive T-LymphocytesForkhead Transcription Factors

Stichwörter der Autor:innen

Locally advanced cervical cancerNeoadjuvant chemotherapyPathological responsePrognosisStromal type

Substanzen

FOXP3 protein, humanForkhead Transcription Factors

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Department of Pathology, Sun Yat-sen University Cancer Center, 651# Dong Feng Road East, Guangzhou, 510060, Guangdong, China.
  • Department of Pathology, The Second Affiliated Hospital of Shenzhen University, Shenzhen, 518101, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. luorzh@sysucc.org.cn.
  • Department of Pathology, Sun Yat-sen University Cancer Center, 651# Dong Feng Road East, Guangzhou, 510060, Guangdong, China. luorzh@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liulil@sysucc.org.cn.

ORCID-Profile: Li-Li Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wei, L. J., Fu, J., Yang, H. X., Yang, X., Liang, H. Y., Luo, R. Z., & Liu, L. L. (2024). Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05482-3

Vancouver

Wei LJ, Fu J, Yang HX, Yang X, Liang HY, Luo RZ, et al. Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer. Journal of Translational Medicine. 2024. doi:10.1186/s12967-024-05482-3

BibTeX
@article{Wei2024,
  author = {Wei, Li-Jun and Fu, Jia and Yang, Hai-Xia and Yang, Xia and Liang, Hao-Yu and Luo, Rong-Zhen and Liu, Li-Li},
  title = {Evaluation of pathological response to neoadjuvant chemotherapy in locally advanced cervical cancer},
  journal = {Journal of Translational Medicine},
  year = {2024},
  doi = {10.1186/s12967-024-05482-3}
}
Kostenlos starten →